MCID: ACT017
MIFTS: 50

Acute Chest Syndrome

Categories: Cardiovascular diseases, Respiratory diseases

Aliases & Classifications for Acute Chest Syndrome

MalaCards integrated aliases for Acute Chest Syndrome:

Name: Acute Chest Syndrome 12 54 43 15 17 71
Acute Chest Syndrome in Sickle Cell Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1584
ICD9CM 34 517.3
MeSH 43 D056586
NCIt 49 C138179
UMLS 71 C0742343

Summaries for Acute Chest Syndrome

Disease Ontology : 12 A lung disease that involves a vasoocclusive crisis of the pulmonary vasculature seen in patients with sickle cell anemia. The crisis is initiated by a lung infection, and the resulting inflammation and loss of oxygen tension leads to sickling of red cells and further vasoocclusion. The disease has symptom fever, has symptom pleuritic chest pain, has symptom tachypnea, has symptom cough, has symptom hypoxemia, has symptom marked leukocytosis, and has symptom diffuse infiltrates on chest radiograph.

MalaCards based summary : Acute Chest Syndrome, also known as acute chest syndrome in sickle cell disease, is related to sickle cell disease and hemoglobinopathy, and has symptoms including fever, cough and hypoxemia. An important gene associated with Acute Chest Syndrome is NOS3 (Nitric Oxide Synthase 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Tinzaparin and Morphine have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and bone marrow, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 The acute chest syndrome is a vaso-occlusive crisis of the pulmonary vasculature commonly seen in people... more...

Related Diseases for Acute Chest Syndrome

Diseases related to Acute Chest Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 sickle cell disease 32.9 VCAM1 HBB G6PD
2 hemoglobinopathy 30.3 VEGFA VCAM1 HBB G6PD
3 bacterial pneumonia 30.3 CXCL8 CSF3 CD40LG
4 pulmonary hypertension 29.8 VEGFA NOS3 HMOX1 EDN1 CXCL8
5 sickle cell anemia 29.8 VCAM1 NOS3 HMOX1 HBB G6PD EDN1
6 sleep apnea 29.7 VEGFA VCAM1 NOS3 EDN1 CXCL8
7 idiopathic interstitial pneumonia 29.6 VEGFA THBS1 EDN1 CXCL8
8 alpha-thalassemia 29.5 VCAM1 HBB-LCR HBB G6PD
9 pulmonary edema 29.5 NOS3 HMOX1 EDN1 CXCL8 CSF3
10 hemolytic anemia 29.5 HMOX1 HBB G6PD CD40LG
11 lung disease 29.3 VEGFA HMOX1 EDN1 CXCL8 CSF3 CD40LG
12 bacterial infectious disease 28.6 PTX3 IL1A CXCL8 CSF3 CD40LG
13 thrombocytopenia 28.5 THBS1 IL1A CXCL8 CSF3 CD40LG
14 asthma 26.0 VCAM1 PLA2G2A NOS1 IL1A HLA-DRB1 HLA-DQB1
15 sickle cell - hemoglobin d disease 11.5
16 hemoglobin se disease 11.1
17 hemifacial spasm 10.4 VEGFA NOS3
18 engraftment syndrome 10.4 CXCL8 CSF3
19 night blindness, congenital stationary, type 1h 10.4 VCAM1 EDN1
20 erythema elevatum diutinum 10.4 CXCL8 CD40LG
21 respiratory allergy 10.4 NOS3 NOS1 CXCL8
22 sexual disorder 10.4 NOS3 NOS1 EDN1
23 respiratory failure 10.4
24 histiocytosis-lymphadenopathy plus syndrome 10.4 HBB G6PD
25 impotence 10.3 NOS3 NOS1 EDN1
26 achalasia, familial esophageal 10.3 NOS1 HLA-DQB1
27 osteosclerotic myeloma 10.3 VEGFA CD40LG
28 thalassemia 10.3
29 mycobacterium abscessus 10.3 HMOX1 CXCL8
30 eclampsia 10.3 VEGFA NOS3 EDN1
31 ross river fever 10.3 PTX3 CD40LG
32 diabetic polyneuropathy 10.3 VEGFA NOS3 NOS1
33 chronic mountain sickness 10.3 VEGFA NOS3 EDN1
34 plasmodium vivax malaria 10.3 VCAM1 G6PD CD40LG
35 leukostasis 10.3 VEGFA VCAM1 NOS3
36 acute mountain sickness 10.3 VEGFA NOS3 EDN1
37 persistent fetal circulation syndrome 10.2 VEGFA NOS3 EDN1
38 trichosporonosis 10.2 PTX3 CSF3
39 opportunistic mycosis 10.2 CXCL8 CSF3 CD40LG
40 renovascular hypertension 10.2 NOS3 NOS1 HMOX1 EDN1
41 nonarteritic anterior ischemic optic neuropathy 10.2 VEGFA NOS3 EDN1
42 deficiency anemia 10.2
43 hereditary elliptocytosis 10.2 THBS1 HBB G6PD
44 fallopian tube disease 10.2 VEGFA CXCL8 CD40LG
45 intracranial berry aneurysm 10.2 NOS3 HMOX1 EDN1
46 limb ischemia 10.2 VEGFA NOS3 EDN1
47 bilirubin metabolic disorder 10.2 HMOX1 G6PD CD40LG
48 achalasia 10.2 NOS3 NOS1 HLA-DQB1
49 central retinal artery occlusion 10.2 VEGFA HMOX1 CD40LG
50 meconium aspiration syndrome 10.2 PLA2G10 EDN1 CXCL8 CSF3

Graphical network of the top 20 diseases related to Acute Chest Syndrome:



Diseases related to Acute Chest Syndrome

Symptoms & Phenotypes for Acute Chest Syndrome

Symptoms:

12
  • fever
  • cough
  • hypoxemia
  • tachypnea
  • pleuritic chest pain
  • marked leukocytosis
  • diffuse infiltrates on chest radiograph

UMLS symptoms related to Acute Chest Syndrome:


dyspnea, apnea, hemoptysis, cheyne-stokes respiration, coughing, hoarseness

MGI Mouse Phenotypes related to Acute Chest Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 CD40LG EDN1 G6PD HLA-DQB1 HMOX1 IL1A
2 cellular MP:0005384 10.14 CD40LG G6PD HLA-DQB1 HMOX1 NOS1 NOS3
3 hematopoietic system MP:0005397 10.13 CD40LG CSF3 G6PD HLA-DQB1 HMOX1 IL1A
4 endocrine/exocrine gland MP:0005379 10.07 CD40LG EDN1 HLA-DQB1 HMOX1 NOS1 NOS3
5 immune system MP:0005387 10.03 CD40LG CSF3 HLA-DQB1 HMOX1 IL1A NOS1
6 muscle MP:0005369 9.76 EDN1 HLA-DQB1 HMOX1 NOS1 NOS3 PLA2G10
7 renal/urinary system MP:0005367 9.61 CD40LG CSF3 EDN1 HLA-DQB1 HMOX1 NOS1
8 reproductive system MP:0005389 9.32 CD40LG HLA-DQB1 HMOX1 NOS1 NOS3 PLA2G10

Drugs & Therapeutics for Acute Chest Syndrome

Drugs for Acute Chest Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
2
Morphine Approved, Investigational Phase 3 57-27-2 5288826
3
Nalbuphine Approved Phase 3 20594-83-6 5360630 5311304
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
7 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
8
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
13
Atorvastatin Approved Phase 3 134523-00-5 60823
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
17 Anti-Asthmatic Agents Phase 2, Phase 3
18 Respiratory System Agents Phase 2, Phase 3
19 Free Radical Scavengers Phase 2, Phase 3
20 Antioxidants Phase 2, Phase 3
21 Protective Agents Phase 2, Phase 3
22 Bronchodilator Agents Phase 2, Phase 3
23 Narcotics Phase 3
24 Analgesics, Opioid Phase 3
25 Methylprednisolone Acetate Phase 3
26 Neuroprotective Agents Phase 3
27 Vaccines Phase 2, Phase 3
28 Immunologic Factors Phase 2, Phase 3
29 Fibrinolytic Agents Phase 3
30 Platelet Aggregation Inhibitors Phase 3
31 Anticholesteremic Agents Phase 3
32 Analgesics, Non-Narcotic Phase 3
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3
34 Hypolipidemic Agents Phase 3
35 Cyclooxygenase Inhibitors Phase 3
36 Antipyretics Phase 3
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
38 Lipid Regulating Agents Phase 3
39 Autonomic Agents Phase 3
40 Hormone Antagonists Phase 3
41 Anti-Inflammatory Agents Phase 3
42 glucocorticoids Phase 3
43 Hormones Phase 3
44 Antiemetics Phase 3
45 HIV Protease Inhibitors Phase 3
46 Gastrointestinal Agents Phase 3
47
protease inhibitors Phase 3
48 BB 1101 Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50
Melphalan Approved Phase 2 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults Unknown status NCT02580773 Phase 3 Prophylactic anticoagulation ( INNOHEP®);Curative anticoagulation ( INNOHEP®)
2 Bicentric Study of the Effect of Inhaled Nitric Oxide Compared to Placebo in Acute Chest Syndrome of Adult Sickle Cell Patients Completed NCT00748423 Phase 2, Phase 3 Nitric Oxide;Placebo
3 Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT02449616 Phase 3 MST-188
4 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis Completed NCT01737814 Phase 3 Saline;MST-188
5 Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Completed NCT00006400 Phase 3 Hydroxyurea;Placebo
6 Choosing Opioid Management for Pain and Analyzing ACS Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain
7 Randomized Trial of High-dose Intravenous Methylprednisolone and Steroid Taper for Vaso-occlusive Crises in Sickle Cell Disease Completed NCT00263562 Phase 3 Methylprednisolone plus prednisone taper
8 Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study Active, not recruiting NCT03128515 Phase 3 Hydroxyurea
9 Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II Active, not recruiting NCT02560935 Phase 3 Hydroxyurea (Moderate Dose);Hydroxyurea (Low Dose)
10 Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial Active, not recruiting NCT03666806 Phase 2, Phase 3
11 Investigator-initiated, Placebo-controlled, Randomized Trial to Assess the Efficacy and Safety of Platelet Inhibition and/ or Lipid Lowering in Non-ACS-patients With Elevated High-sensitivity Troponin Values Not yet recruiting NCT03820466 Phase 3 Aspirin;Atorvastatin;Placebo Aspirin;Placebo Atorvastatin
12 Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) Not yet recruiting NCT04084080 Phase 3
13 Randomized Trial of Oral Dexamethasone for Acute Chest Syndrome Terminated NCT00530270 Phase 3 Dexamethasone;Placebo
14 Protocol for the Administration of Hydroxyurea During Painful Vaso-occlusive Crisis in Sickle Cell Anemia Unknown status NCT03062501 Phase 2 Hydroxyurea
15 HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Unknown status NCT02776202 Phase 2 Fludarabine monophosphate
16 Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children: Randomized, Double Blind Placebo-controlled Concept-proof Trial Completed NCT01089439 Phase 2 Nitric oxide by inhalation INOMAX;Placebo
17 Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease Completed NCT00029731 Phase 2 Arginine hydrochloride
18 IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis) Completed NCT00434473 Phase 2 A-001
19 Targeted Delivery of Nitric Oxide by Hemoglobin to Improve Regional Blood Flow in Sickle Cell Disease Completed NCT00009581 Phase 2 L-NMMA;Acetylcholine
20 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease Completed NCT01054768 Phase 2 Placebo
21 Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study Subjects With Sickle Cell Anemia Completed NCT00001716 Phase 2 Nitric Oxide;Nitroglycerin
22 Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo Completed NCT01419977 Phase 2 Placebo;Dalteparin
23 SC Youth Treatment With Hydroxyurea Effects Completed NCT02336373 Phase 2 hydroxyurea
24 Pilot Study of Vitamin D Therapy to Prevent Respiratory Complications in Children With Sickle Cell Disease Completed NCT01276587 Phase 1, Phase 2 Vitamin D3
25 Assessment of Computerized Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in Subjects With Sickle Cell Disease Completed NCT02225132 Phase 1, Phase 2 Hydroxyurea
26 An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease Completed NCT01375608 Phase 2 Decitabine
27 A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia Completed NCT01788631 Phase 2 Regadenoson;Placebo
28 A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome Recruiting NCT03805581 Phase 2 Defibrotide
29 A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD) Recruiting NCT03719729 Phase 2 Rifaximin
30 Vitamin D for Sickle-cell Respiratory Complications Active, not recruiting NCT01443728 Phase 2 Experimental: Vitamin D3 100,000 IU;Active Comparator: Vitamin D3 12,000 IU
31 Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children Active, not recruiting NCT01389024 Phase 2 Hydroxyurea;Placebo
32 Daily Vitamin D for Sickle-cell Respiratory Complications Not yet recruiting NCT04170348 Phase 2 Daily oral vitamin D3, 3,333 IU;Bolus oral vitamin D3, 100,000 IU;Placebo oral tablet
33 A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects. Terminated NCT01522196 Phase 2 Varespladib
34 Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs. Standard of Care in Acute Chest Syndrome Terminated NCT02098993 Phase 2 Unfractionated heparin
35 Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial Terminated NCT00532883 Phase 2 Hydroxyurea;Magnesium Pidolate
36 Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study Terminated NCT00595530 Phase 2 ketamine
37 Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy Terminated NCT00492531 Phase 2 Sildenafil;Placebo
38 SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease Terminated NCT02013375 Phase 2 Alemtuzumab;Cyclophosphamide;Sirolimus
39 Treatment of Adult Patients With Hemoglobin SC Disease Terminated NCT02640573 Phase 2 Hydroxyurea
40 Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease: a Feasibility Trial Withdrawn NCT02960503 Phase 1, Phase 2 Azithromycin
41 A Phase 1 Dose Escalation Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome Completed NCT02697240 Phase 1 Intravenous citrulline
42 Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial Completed NCT02187445 Phase 1 Budesonide inhalation suspension
43 Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease Completed NCT01895998 Phase 1 Albuterol
44 Aspirin Prophylaxis in Sickle Cell Disease Completed NCT00178464 Phase 1 aspirin
45 Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension Completed NCT00023296 Phase 1 Nitric Oxide
46 Hematopoietic Stem Cell Transplantation for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Doppler Ultrasound Using Reduced-Intensity Conditioning and T-Cell Depleted HSC From Partially Matched Family Donors Completed NCT00152113 Phase 1 See intervention description
47 Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension Completed NCT00352430 Phase 1 Nitric Oxide/INP Pulse Delivery;Nitric Oxide/INO Pulse Delivery
48 Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study Completed NCT00968162 Phase 1 fludarabine
49 Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Completed NCT02989701 Phase 1 Plerixafor
50 The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease Enrolling by invitation NCT02651272 Phase 1 macitentan

Search NIH Clinical Center for Acute Chest Syndrome

Cochrane evidence based reviews: acute chest syndrome

Genetic Tests for Acute Chest Syndrome

Anatomical Context for Acute Chest Syndrome

MalaCards organs/tissues related to Acute Chest Syndrome:

40
Lung, Bone, Bone Marrow, Kidney, Endothelial, Heart, Placenta

Publications for Acute Chest Syndrome

Articles related to Acute Chest Syndrome:

(show top 50) (show all 951)
# Title Authors PMID Year
1
Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms. 54 61
17351927 2007
2
ET-1 and ecNOS gene polymorphisms andsusceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. 54 61
16956834 2006
3
Elevated plasma sVCAM-1 levels in children with sickle cell disease: impact of chronic transfusion therapy. 54 61
15114598 2004
4
Sera of patients suffering from inflammatory diseases contain group IIA but not group V phospholipase A(2). 54 61
11040450 2000
5
Molecular testing for respiratory pathogens in sickle cell disease adult patients presenting with febrile acute chest syndrome. 61
31088757 2020
6
Patients With Sickle Cell Disease Between Ages 0 and 20 Years Presenting With Acute Chest Syndrome in the United States. 61
31990791 2020
7
Platelet Extracellular Vesicles Drive Inflammasome-IL-1β-Dependent Lung Injury in Sickle Cell Disease. 61
31498653 2020
8
Prevalence and Risk Factors for Microalbuminuria in Children with Sickle Cell Disease at King Abdulaziz University Hospital: A Retrospective Cross-sectional Study. 61
31966947 2020
9
Blood transfusions for treating acute chest syndrome in people with sickle cell disease. 61
31942751 2020
10
Maternal sickle cell disease and twin pregnancy: a case series and review of the literature. 61
30345909 2019
11
Treatment for avascular necrosis of bone in people with sickle cell disease. 61
31803937 2019
12
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. 61
31742673 2019
13
Comparison of pneumococcal vaccination response in children with sickle cell disease: HbSS and HbSC. 61
31164233 2019
14
Nucleated Red Blood Cells in Children With Sickle Cell Disease Hospitalized for Pain. 61
30951023 2019
15
Identification of Clinical and Laboratory Parameters Associated with the Development of Acute Chest Syndrome during Vaso-Occlusive Episodes in Children with Sickle Cell Disease: A Preliminary Step before Assessing Specific and Early Treatment Strategies. 61
31683997 2019
16
Sickle cell disease: current treatment and emerging therapies. 61
31809007 2019
17
Association between MTHFR 677C>T polymorphism and vascular complications in sickle cell disease: A meta-analysis. 61
30686687 2019
18
Systemo-pulmonary shunting and acute chest syndrome in a patient with SC sickle-cell disease. 61
32036282 2019
19
Indications for RBC Exchange Transfusion in Patients with Sickle Cell Disease: Revisited. 61
31882437 2019
20
Acute Chest Syndrome in Sickle Cell Disease. 61
31744621 2019
21
Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. 61
31698459 2019
22
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. 61
31744266 2019
23
Hematologic Conditions: Common Hemoglobinopathies. 61
31613565 2019
24
Antibiotic Use and Respiratory Pathogens in Adults With Sickle Cell Disease and Acute Chest Syndrome. 61
31014083 2019
25
Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. 61
31129243 2019
26
Evaluation of a Non-Parenteral Opioid Analgesia Protocol for Acute Sickle Cell Pain Episodes in Children. 61
31635344 2019
27
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria. 61
31608959 2019
28
Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. 61
31619251 2019
29
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). 61
31446143 2019
30
Identification and Characterization of Hematopoietic Stem Cell Transplant Candidates in a Sickle Cell Disease Cohort. 61
31229639 2019
31
Integrating Fat Embolism Syndrome Scoring Indices in Sickle Cell Disease: A Practice Management Review. 61
28662607 2019
32
Inhaled nitric oxide for treating pain crises in people with sickle cell disease. 61
31603241 2019
33
Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. 61
31469310 2019
34
Outcome of Pregnancy in Saudi Women with Sickle Cell Disease Attending the Tertiary Care University Hospital in Eastern Province of Saudi Arabia. 61
31782630 2019
35
Morpho-functional evaluation of lung aeration as a marker of sickle-cell acute chest syndrome severity in the ICU: a prospective cohort study. 61
31565756 2019
36
Lung ultrasound in children: What does it give us? 61
31679983 2019
37
Antibiotics for treating acute chest syndrome in people with sickle cell disease. 61
31531967 2019
38
Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy. 61
31157521 2019
39
High incidence of venous thromboembolism recurrence in patients with sickle cell disease. 61
31074115 2019
40
Improving the Care of Individuals With Sickle Cell Disease in the Emergency Department Using a Quality Improvement Framework: The Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS). 61
31356252 2019
41
Ultrasound-guided recruitment maneuvers in pediatric acute chest syndrome due to sickle cell disease. 61
31331675 2019
42
A physicians survey assessing management of pulmonary airway involvement in sickle cell disease. 61
31012283 2019
43
Marijuana-induced Coronary Vasospasm with Persistent Inter-coronary Connection: A Case Report and Review of Literature. 61
31497413 2019
44
Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. 61
30768787 2019
45
Successful Treatment of Acute Chest Syndrome with Manual Exchange Transfusion in a Patient with Sickle Beta+-thalassemia. 61
30713307 2019
46
Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014. 61
30805858 2019
47
Candida albicans induced acute chest syndrome in sickle cell disease. 61
30900797 2019
48
Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. 61
30740900 2019
49
The erythrocyte alloimmunisation in patients with sickle cell anaemia: a systematic review. 61
29845661 2019
50
Radiological Patterns in Sickle Cell Disease Patients with Acute Chest Syndrome: Are There Age-Related Differences? 61
31080386 2019

Variations for Acute Chest Syndrome

Expression for Acute Chest Syndrome

Search GEO for disease gene expression data for Acute Chest Syndrome.

Pathways for Acute Chest Syndrome

Pathways related to Acute Chest Syndrome according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 VEGFA VCAM1 PTX3 PLA2G2A NOS3 NOS1
2
Show member pathways
13.22 VEGFA VCAM1 IL1A HMOX1 HLA-DRB1 HLA-DQB1
3
Show member pathways
12.74 VEGFA IL1A HLA-DRB1 HLA-DQB1 CXCL8 CD40LG
4
Show member pathways
12.4 PLA2G2A PLA2G10 NOS3 EDN1
5
Show member pathways
12.39 NOS3 NOS1 HMOX1 CXCL8
6
Show member pathways
12.18 IL1A HLA-DRB1 HLA-DQB1 CD40LG
7
Show member pathways
12.14 IL1A HMOX1 EDN1 CXCL8
8 12.06 THBS1 NOS1 HLA-DRB1 HLA-DQB1
9 12.04 VCAM1 HLA-DRB1 HLA-DQB1 CD40LG
10 11.93 PLA2G2A NOS1 IL1A CXCL8
11 11.86 VEGFA VCAM1 IL1A HMOX1 CXCL8
12 11.83 VEGFA NOS3 HMOX1 EDN1
13 11.78 VEGFA VCAM1 NOS3 IL1A HMOX1 EDN1
14 11.77 IL1A HLA-DRB1 HLA-DQB1 CSF3
15 11.75 THBS1 NOS3 HMOX1
16 11.73 VEGFA IL1A HLA-DRB1 HLA-DQB1 CXCL8
17 11.66 VEGFA THBS1 CXCL8
18 11.6 VEGFA HMOX1 EDN1
19
Show member pathways
11.52 VEGFA VCAM1 IL1A CXCL8 CD40LG
20 11.51 VEGFA NOS3 EDN1
21 11.45 IL1A CXCL8 CSF3
22 11.45 PTX3 HMOX1 EDN1 CXCL8 CSF3
23 11.43 VEGFA VCAM1 NOS3 IL1A EDN1 CXCL8
24 11.27 NOS3 HMOX1 CXCL8
25 11.17 IL1A HLA-DRB1 CSF3
26 11.13 PLA2G2A NOS3 NOS1
27 10.8 VCAM1 THBS1 HBB CXCL8 CSF3 CD40LG
28 10.75 NOS3 NOS1
29 10.52 NOS3 NOS1

GO Terms for Acute Chest Syndrome

Cellular components related to Acute Chest Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA THBS1 PTX3 PLA2G2A PLA2G10 IL1A
2 extracellular space GO:0005615 9.44 VEGFA VCAM1 THBS1 PTX3 PLA2G2A PLA2G10
3 caveola GO:0005901 9.43 NOS3 NOS1 HMOX1
4 endocytic vesicle membrane GO:0030666 9.33 NOS3 HLA-DRB1 HLA-DQB1

Biological processes related to Acute Chest Syndrome according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.93 VEGFA NOS3 HMOX1 CXCL8
2 inflammatory response GO:0006954 9.93 THBS1 PTX3 IL1A CXCL8 CD40LG
3 response to lipopolysaccharide GO:0032496 9.83 VCAM1 NOS3 NOS1 EDN1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 VEGFA NOS1 CSF3
5 neutrophil chemotaxis GO:0030593 9.81 IL1A EDN1 CXCL8
6 cellular response to heat GO:0034605 9.79 THBS1 IL1A HMOX1
7 interferon-gamma-mediated signaling pathway GO:0060333 9.79 VCAM1 HLA-DRB1 HLA-DQB1
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 THBS1 HMOX1 EDN1
9 positive regulation of endothelial cell migration GO:0010595 9.74 VEGFA THBS1 EDN1
10 cellular response to tumor necrosis factor GO:0071356 9.73 VCAM1 THBS1 EDN1 CXCL8
11 cytokine-mediated signaling pathway GO:0019221 9.73 VEGFA VCAM1 IL1A HMOX1 CXCL8 CSF3
12 immune response GO:0006955 9.7 THBS1 IL1A HLA-DRB1 HLA-DQB1 CXCL8 CSF3
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.69 VEGFA THBS1 NOS3
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 PTX3 HBB EDN1
15 induction of positive chemotaxis GO:0050930 9.65 VEGFA CXCL8
16 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.65 HLA-DRB1 HLA-DQB1
17 nitric oxide biosynthetic process GO:0006809 9.65 NOS3 NOS1
18 response to nicotine GO:0035094 9.65 VCAM1 HMOX1 EDN1
19 positive regulation of guanylate cyclase activity GO:0031284 9.63 NOS3 NOS1
20 negative regulation of potassium ion transport GO:0043267 9.62 NOS3 NOS1
21 regulation of blood pressure GO:0008217 9.62 NOS3 HMOX1 HBB EDN1
22 chronic inflammatory response GO:0002544 9.61 VCAM1 THBS1
23 negative regulation of hydrolase activity GO:0051346 9.6 NOS3 NOS1
24 positive regulation of prostaglandin secretion GO:0032308 9.59 PLA2G10 EDN1
25 arginine catabolic process GO:0006527 9.58 NOS3 NOS1
26 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.56 NOS3 EDN1
27 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.55 HLA-DRB1 HLA-DQB1
28 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.46 HLA-DRB1 HLA-DQB1
29 response to hypoxia GO:0001666 9.43 VEGFA VCAM1 THBS1 NOS1 HMOX1 EDN1
30 nitric oxide transport GO:0030185 9.4 HBB EDN1
31 smooth muscle hyperplasia GO:0014806 9.37 NOS3 HMOX1
32 positive regulation of angiogenesis GO:0045766 9.1 VEGFA THBS1 NOS3 IL1A HMOX1 CXCL8

Molecular functions related to Acute Chest Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.56 NOS3 NOS1 HMOX1 HBB
2 MHC class II receptor activity GO:0032395 9.46 HLA-DRB1 HLA-DQB1
3 arginine binding GO:0034618 9.43 NOS3 NOS1
4 NADPH-hemoprotein reductase activity GO:0003958 9.4 NOS3 NOS1
5 cadmium ion binding GO:0046870 9.37 NOS3 NOS1
6 NADP binding GO:0050661 9.33 NOS3 NOS1 G6PD
7 tetrahydrobiopterin binding GO:0034617 9.32 NOS3 NOS1
8 cytokine activity GO:0005125 9.1 VEGFA IL1A EDN1 CXCL8 CSF3 CD40LG
9 nitric-oxide synthase activity GO:0004517 8.96 NOS3 NOS1

Sources for Acute Chest Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....